Year archive

Can-Fite BioPharma Ltd. — 2026 filings

All 72 regulatory filings released by Can-Fite BioPharma Ltd. (CANF) in 2026, sourced directly from the official regulator.

72 Filings

2026 Period

2026 filings (72)

Filing	Released	Lang
Immediate Report Regulatory Filings	2026-05-28	English
Immediate Report Declaration of Voting Results & Voting Rights Announcements	2026-05-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2026-05-28	English
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market2 Regulatory Filings	2026-05-18	English
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market2 Report Publication Announcement	2026-05-18	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2026-05-18	English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer) Regulatory Filings	2026-05-13	English
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy Regulatory Filings	2026-05-13	English
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy Report Publication Announcement	2026-05-13	English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer) Regulatory Filings	2026-04-30	English
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months Regulatory Filings	2026-04-30	English
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months Regulatory Filings	2026-04-30	English
Immediate Report of Meeting to be held on ON MAY 28, 2026, proxy statement Proxy Solicitation & Information Statement	2026-04-24	English
Immediate Report of Meeting to be held on ON MAY 28, 2026, proxy statement Proxy Solicitation & Information Statement	2026-04-24	English
Immediate Report of Meeting to be held on ON MAY 28, 2026, proxy statement Proxy Solicitation & Information Statement	2026-04-24	English
Annual General Meeting of Shareholders will be held on May 28, 2026 Proxy Solicitation & Information Statement	2026-04-24	English
Annual General Meeting of Shareholders will be held on May 28, 2026 Proxy Solicitation & Information Statement	2026-04-24	English
Other Report or Announcement Capital/Financing Update	2026-04-04	English
Other Report or Announcement Report Publication Announcement	2026-04-04	English
424B3 - Can-Fite BioPharma Ltd. (0001536196) (Filer) Regulatory Filings	2026-04-03	English
Other Report or Announcement Capital/Financing Update	2026-03-30	Hebrew (modern)
Other Report or Announcement Report Publication Announcement	2026-03-30	English
Other Report or Announcement Regulatory Filings	2026-03-30	English
Other Report or Announcement Report Publication Announcement	2026-03-30	English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer) Regulatory Filings	2026-03-30	English
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 Regulatory Filings	2026-03-30	English
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 Report Publication Announcement	2026-03-30	English
20-F - Can-Fite BioPharma Ltd. (0001536196) (Filer) Annual Report FY 2025	2026-03-26	English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer) Regulatory Filings	2026-03-26	English
20-F FOR 2025 Annual Report FY 2025	2026-03-26	Hebrew (modern)
20-F FOR 2025 Report Publication Announcement	2026-03-26	English
2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient Earnings Release FY 2025	2026-03-26	English
2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient Report Publication Announcement	2026-03-26	English
3 - Can-Fite BioPharma Ltd. (0001536196) (Issuer) Director's Dealing	2026-03-18	English
3 - Can-Fite BioPharma Ltd. (0001536196) (Issuer) Director's Dealing	2026-03-18	English
3 - Can-Fite BioPharma Ltd. (0001536196) (Issuer) Director's Dealing	2026-03-18	English
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance Regulatory Filings	2026-03-17	English
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance Report Publication Announcement	2026-03-17	English
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer) Regulatory Filings	2026-03-17	English
Other Report or Announcement Declaration of Voting Results & Voting Rights Announcements	2026-03-10	English
Other Report or Announcement Declaration of Voting Results & Voting Rights Announcements	2026-03-10	English
424b3 Prospectus supplement Capital/Financing Update	2026-03-05	English
424b3 Prospectus supplement Report Publication Announcement	2026-03-05	English
6K-Exercise of Warrants, expects to receive aggregate gross proceeds of approximately $4.0 million Capital/Financing Update	2026-03-05	English
6K-Exercise of Warrants, expects to receive aggregate gross proceeds of approximately $4.0 million Report Publication Announcement	2026-03-05	English
Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds Capital/Financing Update	2026-03-05	English
Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds Report Publication Announcement	2026-03-05	English
In light of trading halt on AMEX, trading was also haltes in TASE Regulatory Filings	2026-03-04	English
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study Regulatory Filings	2026-03-04	English
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study Report Publication Announcement	2026-03-04	English
The Meeting was adjourned and place due on March 10, 2026 to lack of quorum AGM Information	2026-03-04	English
The Meeting was adjourned and place due on March 10, 2026 to lack of quorum Report Publication Announcement	2026-03-04	English
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson Regulatory Filings	2026-02-17	English
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson Regulatory Filings	2026-02-17	English
6-K Filing Regulatory Filings	2026-02-17	English
Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy Regulatory Filings	2026-02-09	English
Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy Regulatory Filings	2026-02-09	English
6-K Filing Regulatory Filings	2026-02-09	English
Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson Regulatory Filings	2026-02-05	English
Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson Regulatory Filings	2026-02-05	English
6-K Filing Regulatory Filings	2026-02-05	English
Immediate Report of Meeting Proxy Solicitation & Information Statement	2026-01-27	English
Immediate Report of Meeting Director's Dealing	2026-01-27	English
Immediate Report of Meeting Proxy Solicitation & Information Statement	2026-01-27	English
Immediate Report of Meeting AGM Information	2026-01-27	English
6-K Filing Regulatory Filings	2026-01-27	English
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson Regulatory Filings	2026-01-20	English
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson Report Publication Announcement	2026-01-20	English
6-K Filing Regulatory Filings	2026-01-20	English
Other Report or Announcement Board/Management Information	2026-01-16	English
Other Report or Announcement Board/Management Information	2026-01-16	English
6-K Filing Regulatory Filings	2026-01-16	English

Filings by year

2026 72 filings
2025 144 filings
2024 140 filings
2023 170 filings
2022 110 filings
2021 151 filings
2020 315 filings
2019 251 filings
2018 150 filings
2017 166 filings
2016 178 filings
2015 160 filings
2014 129 filings
2013 34 filings
2012 2 filings